



YF-Vax[®] – Drug shortage

- The [drug shortage](#) of [YF-Vax \(yellow fever virus strain 17d-204 live antigen\)](#) is ongoing. YF-Vax has been unavailable for at least 90 days and is due to production delays.
 - Sanofi Pasteur has YF-Vax multi-dose vials and single dose vials on back order and the company cannot estimate a release date.
- YF-Vax is indicated for active immunization for the prevention of yellow fever in persons 9 months of age and older in the following categories: persons living in or traveling to yellow fever endemic areas, persons traveling internationally through countries with yellow fever, and laboratory personnel who handle virulent yellow fever virus or concentrated preparations of the yellow fever vaccine virus strains.

Product Description	NDC #
YF-Vax (yellow fever virus strain 17-d-2014 live antigen) single- and multi-dose vials	49281-0915-01; 49281-0915-05

- Sanofi Pasteur has worked with the FDA to make [Stamaril[®] \(yellow fever virus strain 17d-204 live antigen\)](#), a foreign, non-FDA approved drug available. Clinics providing access to Stamaril can be found [here](#). Stamaril is not therapeutically equivalent to YF-Vax; however, the two products carry the same indication.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.